Forrest defines the parameters that are expected to drive the rate of resistance observed clinically and establish a quantitative estimate of risk of the emergence of drug resistance in clinical use to Pretomanid and a larger panel of compounds in development.
![Forrest Hopkins](https://www.hsph.harvard.edu/fortune-lab/wp-content/uploads/sites/2421/2017/06/IMG_0745-300x300.jpg)